Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O15554
UPID:
KCNN4_HUMAN
Alternative names:
IKCa1; KCa3.1; KCa4; Putative Gardos channel
Alternative UPACC:
O15554; Q53XR4
Background:
Intermediate conductance calcium-activated potassium channel protein 4, also known as IKCa1, KCa3.1, KCa4, or the Putative Gardos channel, plays a pivotal role in cellular processes. It forms a voltage-independent potassium channel activated by intracellular calcium, leading to membrane hyperpolarization and subsequent calcium influx. This protein is crucial for T-cell reactivation and proliferation, and it also contributes to the late stages of EGF-induced macropinocytosis.
Therapeutic significance:
The protein's involvement in Dehydrated hereditary stomatocytosis 2, a condition characterized by hemolytic anemia due to erythrocyte dehydration, underscores its therapeutic potential. Targeting KCa3.1 could offer novel treatment avenues for managing this genetic disorder and its complications, such as splenomegaly and cholelithiasis.